论文部分内容阅读
目的:观察泰勒宁与美施康定治疗中、重度癌痛的疗效及毒副反应,并评价2种药物在癌症三阶梯止痛中的地位。方法:患者随机分为泰勒宁组42例(每次口服泰勒宁1粒,q6h,连用5d)和美施康定组45例(首用20mg·d-1,若疼痛缓解,则继续维持治疗,若24h疼痛缓解不明显,则进一步增加剂量直至获得满意的疼痛缓解效果或至最大剂量(最大剂量270mg·d-1))。结果:泰勒宁组中达CR34例,PR4例,NC4例,疼痛缓解有效率为90.48%。美施康定组中达CR37例,PR5例,NC3例,疼痛缓解有效率为93.33%。经统计学比较两组疗效差异无显著性(P>0.05)。结论:泰勒宁和美施康定治疗中、重度癌痛效果大致相当,但泰勒宁依从性好,不良反应发生率较低,程度轻,短期应用未发现对重要脏器有明显影响。
OBJECTIVE: To observe the curative effect and adverse reactions of Tyrannin and mesylate on the treatment of moderate and severe cancer pain, and to evaluate the two drugs’ status in three-stage cancer pain relief. Methods: The patients were randomly divided into two groups: 42 patients in the Taylor group (1 tablet of tylosin per day, q6h for 5 days) and 45 cases of the first dose of 20 mg · d-1. If the pain was relieved, 24h pain relief is not obvious, then further increase the dose until a satisfactory pain relief or to the maximum dose (maximum dose of 270mg · d-1)). Results: Tailuning group reached CR34 cases, PR4 cases, NC4 cases, pain relief effective rate was 90.48%. Among the 37 cases of CRS, PR5 cases and NC3 cases, the effective rate of pain relief was 93.33%. The statistical difference between the two groups showed no significant difference (P> 0.05). Conclusion: Tyrannone and mesylate have similar effect on moderate and severe cancer pain. However, Tyrannine has good compliance and low incidence of adverse reactions. Light and short-term application has not found obvious effect on important organs.